AEterna Zentaris (NASDAQ: AEZS) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Earnings & Valuation
This table compares AEterna Zentaris and AC Immune’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AEterna Zentaris||$910,000.00||30.53||-$24.95 million||($1.81)||-0.93|
|AC Immune||$23.55 million||29.03||-$7.20 million||($0.69)||-17.41|
This table compares AEterna Zentaris and AC Immune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for AEterna Zentaris and AC Immune, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AEterna Zentaris presently has a consensus target price of $3.50, suggesting a potential upside of 107.10%. AC Immune has a consensus target price of $18.00, suggesting a potential upside of 49.88%. Given AEterna Zentaris’ higher probable upside, research analysts plainly believe AEterna Zentaris is more favorable than AC Immune.
Institutional & Insider Ownership
2.0% of AEterna Zentaris shares are owned by institutional investors. Comparatively, 19.6% of AC Immune shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
AC Immune beats AEterna Zentaris on 7 of the 11 factors compared between the two stocks.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
About AC Immune
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.